List of Tyzeka drug patents

Tyzeka is owned by Novartis.

Tyzeka contains Telbivudine.

Tyzeka has a total of 2 drug patents out of which 0 drug patents have expired.

Tyzeka was authorised for market use on 28 April, 2009.

Tyzeka is available in solution;oral dosage forms.

Tyzeka can be used as treatment of chronic hepatitis b in adult patients.

The generics of Tyzeka are possible to be released after 11 September, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7858594 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(7 months from now)

US7589079 NOVARTIS Crystalline and amorphous forms of beta-L-2′-deoxythymidine
Sep, 2023

(7 months from now)

Drugs and Companies using TELBIVUDINE ingredient

Market Authorisation Date: 28 April, 2009

Treatment: Treatment of chronic hepatitis b in adult patients

Dosage: SOLUTION;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic